Business
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibitors for HBV and hepatitis D virus (HDV) First data presented on novel series of orally bioavailable small molecule interferon-a receptor (IFNAR) agonists designed to inhibit HBV and engage the immune system with potential to offer improved tolerability SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported clinical and preclinical data from its virology portfolio at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®. The new data are being presented at the conference as part of four poster presentations, including two late breaker presentations. “The data presented at AASLD’s The Liver Meeting demonstrate the significant progress that we are making in advancing and broadening our early-stage virology programs. These presentations highlight the strength of our research capabilities and the deep virology experience across the team,” said William Delaney, PhD, chief scientific officer of Assembly Bio. “Preclinical data presented from our 4334 program further demonstrate and detail the activity of this next-generation core inhibitor that has been optimized for significantly increased potency against cccDNA formation. Additionally, the first presentation of preclinical data from our small molecule HBV/HDV entry inhibitor and IFNAR agonist programs provides support for our continued advancement of these approaches toward clinical development. We remain committed to our goal of discovering and developing novel antivirals that change the treatment paradigm for serious viral diseases. We are particularly focused on the urgent need for curative and finite therapies for chronic hepatitis B patients and better treatment options for patients chronically infected with HDV.” In the poster entitled “ABI-4334, a novel hepatitis B core inhibitor, accelerates capsid assembly and inhibits cccDNA formation via multiple pathways,”...